---
title: Personalize stimulation to reduce tremor
nct_id: NCT07485621
status: RECRUITING
sponsor: Loes Laurijssen
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07485621"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07485621"
last_fetched: "2026-05-10T14:04:38.216Z"
source: "Parkinson's Pathways (curated)"
---
# Personalize stimulation to reduce tremor

**Goal (in five words):** Personalize stimulation to reduce tremor

**Official Title:** Assessing the Relation Between Subcortical LFPs and DBS Parameter Selection in Parkinson's Disease - a Prospective Study

**Trial ID:** [NCT07485621](https://clinicaltrials.gov/study/NCT07485621)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Loes Laurijssen
- **Target Enrollment:** 40 participants
- **Start Date:** 2026-03-05
- **Completion Date:** 2029-03
- **Conditions:** Parkinson's Disease (PD)

## Summary For Families

It aims to find out whether tiny electrical rhythms from deep brain areas, called local field potentials or LFPs, can help clinicians choose DBS settings that control tremor, slowness, and stiffness while reducing side effects. Researchers will record LFPs from the implanted DBS electrodes during routine programming and look for patterns, like elevated beta-band activity that links to rigidity and bradykinesia, that predict which contacts, voltages, or frequencies work best. Because LFPs change with levodopa and motor state, the hope is that these signals could help personalize stimulation to work alongside medications, while participants receive standard clinical programming. Adults 18 and older with idiopathic Parkinson disease who are approved for DBS to treat refractory motor symptoms and who understand Dutch or French are eligible; about 40 people will be enrolled.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

1. Voluntary written informed consent of the participant
2. At least 18 years of age at the time of signing the Informed Consent Form (ICF)
3. Diagnosis of idiopathic Parkinson's disease according to the clinical diagnostic criteria of the Movement Disorder Society (MDS)
4. Eligible for DBS to treat refractory PD motor symptoms, as based on multidisciplinary DBS screening
5. Have sufficient understanding of the Dutch and French language to participate in the study

Exclusion Criteria:

* /
```

## Locations (1)

- University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium _(50.8796, 4.7009)_
  - Bart Swinnen, MD, PhD — (CONTACT) — 0031 16343044 — bart.swinnen@uzleuven.be
  - Bart Swinnen, MD, PhD — (PRINCIPAL_INVESTIGATOR)
  - Loes Laurijssen, MD — (SUB_INVESTIGATOR)

## Central Contacts

- Bart Swinnen, MD, PhD — (CONTACT) — 0032 16343044 — bart.swinnen@uzleuven.be

---

*Canonical: https://parkinsonspathways.com/trial/NCT07485621*  
*HTML version: https://parkinsonspathways.com/trial/NCT07485621*  
*Source data: https://clinicaltrials.gov/study/NCT07485621*